Agenus Inc (AGEN) Stock Price & Analysis
Agenus Inc (AGEN) fell 0.96% to USD 3.11 as of June 10, 2026 at 03:39 UTC, according to Nexqual real-time market data.
AGEN last closed at USD 3.14; the session ranged USD 3.11–3.31 on volume of 489,171 shares. Market capitalization is $129.51M, with a 52-week range of USD 2.71–7.34 (NCM). Source: Nexqual, June 10, 2026 at 03:39 UTC.
Key Statistics (as of June 10, 2026 at 03:39 UTC)
| Price | USD 3.11 |
|---|---|
| Change | ▼ 0.96% (down) |
| Previous Close | USD 3.14 |
| Open | USD 3.2 |
| Day Range | USD 3.11 – 3.31 |
| 52-Week Range | USD 2.71 – 7.34 |
| Volume | 489,171 shares |
| Market Cap | $129.51M |
| Exchange | NCM |
Technical Analysis (AGEN)
Nexqual's technical model rates AGEN "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.28 (neutral) |
| vs SMA50 | Below (USD 3.71) |
| MACD | -0.13 (negative) |
Analyst Ratings (AGEN)
Wall Street analysts rate AGEN "Strong Buy" based on 2 analysts, with a mean price target of USD 15.5 (range USD 8–23), per Nexqual as of June 10, 2026 at 03:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 15.5 |
| High Target | USD 23 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (AGEN)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD -0.4 |
| Revenue Estimate | $34.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.03 vs est 1.8 ▼ miss |
| 2025-12-31 | USD 0.68 vs est -1.3 ▲ beat |
| 2025-09-30 | USD -1.16 vs est 2.2 ▼ miss |
| 2025-06-30 | USD -1 vs est 1.35 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:39 UTC.
Financials & Fundamentals (AGEN)
| Total Revenue | $123.87M |
|---|---|
| Revenue Growth (YoY) | +40.20% |
| Gross Margin | +96.90% |
| Operating Margin | +44.62% |
| Profit Margin | +52.16% |
| Current Ratio | 0.38 |
| Total Cash | $35.00M |
| Total Debt | $41.07M |
| Free Cash Flow | $-50.64M |
Source: Nexqual, June 10, 2026 at 03:39 UTC.
Financial Health Score (AGEN)
Nexqual rates Agenus Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:39 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Operating margin 45% |
| Balance Sheet | Mixed — $35M cash vs $41M debt |
| Cash Flow | Weak — FCF negative: -$51M, burning cash |
| Efficiency | Mixed — No data |
Ownership (AGEN)
| Insider Ownership | +6.70% |
|---|---|
| Institutional Ownership | +23.46% |
| Shares Outstanding | 41.64M |
| Float | 38.63M |
| Short % of Float | +13.29% |
Source: Nexqual, June 10, 2026 at 03:39 UTC.
Leadership (AGEN)
Agenus Inc is led by Garo H. Armen (age 72), Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman, per Nexqual as of June 10, 2026 at 03:39 UTC.
| Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman | Garo H. Armen (age 72) |
|---|---|
| Director and President & CEO of MiNK Therapeutics | Jennifer S. Buell (age 50) |
Major Backers & Investors (AGEN)
Notable institutional backers of Agenus Inc include Siren, L.L.C., Marshall Wace LLP, Morgan Stanley, according to Nexqual as of June 10, 2026 at 03:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Siren, L.L.C. | 2.56% |
| Marshall Wace LLP | 1.65% |
| Morgan Stanley | 0.71% |
| Renaissance Technologies | 0.69% |
| Man Group PLC | 0.67% |
| Raymond James Financial, Inc. | 0.58% |
| Fidelity | 0.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 12.5% |
| BlackRock | 1.51% |
| Geode Capital | 0.84% |
Source: Nexqual, June 10, 2026 at 03:39 UTC.
From Agenus Inc's Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally.
- It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
- It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
- In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BCRX | BioCryst Pharmaceuticals, Inc. | USD 8.33 | ▼ 0.95% |
| GERN | Geron Corporation | USD 1.12 | ▼ 4.27% |
| CRIS | Curis, Inc. | USD 0.45 | ▼ 4.87% |
| CLDX | Celldex Therapeutics, Inc. | USD 29.6 | ▲ 3.42% |
| ACAD | ACADIA Pharmaceuticals Inc. | USD 21.84 | ▲ 1.3% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:39 UTC. This page is informational and not investment advice.